Skip to content

Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution

Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution: A Randomised Double-Blind, Placebo-controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06400394
Acronym
Plasso 2
Enrollment
116
Registered
2024-05-06
Start date
2024-09-01
Completion date
2026-05-01
Last updated
2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection

Keywords

Peritonitis Peritoneal lavage surgical site infection super-oxidised solution

Brief summary

This is randomised double blinded placebo-controlled parallel-group study. Patients in Hospital Queen Elizabeth, Sabah and Hospital Universiti Sains Malaysia, Kelantan who undergo laparotomy for peritonitis will be equally randomised into two groups : intervention group receiving super-oxidised solution and the control group receiving normal saline during peritoneal and wound lavage. This is a superiority study assessing the effectiveness of the intervention. The patient and doctors directly involved in the partient care will be blinded in this study

Detailed description

OBJECTIVES PrimaryOutcome: To evaluate the effectiveness of peritoneal lavage with superoxidised solution in reducing incidence of surgical site infection after open surgery for peritonitis. SecondaryOutcome: i.To evaluate the effectiveness of peritoneal lavage with super-oxidised solution in reducing inflammatory markers C-reactive protein(CRP) at 24 and 48 hours after open surgery for peritonitis ii.To evaluate the effectiveness of peritoneal lavage with super oxidised solution in reducing duration of post-operative ileus after open surgery for peritonitis. METHODOLOGY Study Design This is a randomised double blind placebo controlled parallel group study. This is a superiority study assessing the effectiveness of the intervention. The patients and doctors directly involved in the patient care will be blinded in this study. Masking Study participants were randomly assigned following computerized block randomization using the website www.randomization.com with a block size of 8 and allocation ratio of 1:1. Allocation sequence and concealment will be performed by the research staff from the Clinical Research Centre who had no clinical involvement in the trial. The allocation sequence will be concealed from the researcher enrolling and assessing the participants in sequentially numbered, opaque, sealed envelopes. The study participants, healthcare providers who attend to the participants during the trial (surgeon and nurses), outcome evaluators (surgical doctors and nurses) and data collectors will be blinded to the allocation. 2 arms with 56 participants per arm Study group: Peritoneal lavage with super-oxidised solution of at least 1L and wound lavage with super-oxidised solution of 500ml \[Super-oxidised solution used in this study is Hydrocyn Aqua® (Vigilenz MD., Penang, Malaysia)\] Control group: Peritoneal lavage with normal saline 0.9% 1L and wound lavage with normal saline 0.9% 500ml Enrollment The estimated total number of participants to be enrolled is about 116 with 20% dropout rate

Interventions

DEVICEHydrocyn Aqua®

The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure

DEVICENormal Saline

aqueous solution of electrolytes and other hydrophilic molecules

Sponsors

Hospital Queen Elizabeth, Malaysia
CollaboratorOTHER_GOV
Universiti Sains Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

computerized block randomization using the website www.randomization.com with a block size of 8 and allocation ratio of 1:1

Intervention model description

a randomised double blind placebo controlled parallel group study

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients age 13yrs and above 2. Diagnosed with perforated viscus intraoperatively 3. Undergo Midline Laparotomy 4. ASA 3 and below

Exclusion criteria

1. Surgical technique: Laparoscopic washouts 2. Patients on steroid treatment and immunosuppressant therapy. 3. More than ASA 3 4. Inability to give/understand informed consent 5. Revision-surgery (previous abdominal surgery within the last 30 days) 6. Planned re-laparotomy within 30 days 7. Terminal kidney failure requiring dialysis 8. Concurrent abdominal wall infections

Design outcomes

Primary

MeasureTime frameDescription
SSI Incidence30 daysTo evaluate the effectiveness of peritoneal lavage with superoxidised solution in reducing incidence of surgical site infection after open surgery for perforated viscus.

Secondary

MeasureTime frameDescription
CRP Level24-48 hrsTo evaluate the effectiveness of peritoneal lavage with super-oxidised solution in reducing inflammatory markers C-reactive protein(CRP) at 24 and 48 hours after open surgery for perforated viscus
Flatus time1-2 daysTo evaluate the effectiveness of peritoneal lavage with super oxidised solution in reducing duration of post-operative ileus after open surgery for perforated viscus.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026